A recent study has shown that a glycolysis inhibitor, 2-Deoxy-D-glucose (2-DG), has the threptic potential to reverse tumorigenicity and sorafenib resistance mediated by protein arginine methyltransferase (PRMT6) deficiency in HCC [37]. This evidence concerns the gene PRMT6 and hepatocellular carcinoma.